ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pulmonary"

  • Abstract Number: 0015 • ACR Convergence 2020

    COVID -19 Lung Inflammation – What Have We Learnt so Far ?

    Sriya Gokaraju1, Maria Darda2, Vinod Vijayaraghavan Nalini Warrier3, Irina Duta3, Fiona Hayes3, Yasser Ahmed4 and Gouri Koduri3, 1Southend University Hospital NHS Trust, Essex, United Kingdom, 2Southend University Hospital NHS Trust, Essex, United Kingdom, 3Southend University Hospital NHS Trust, Essex, United Kingdom, 4Southend University Hospital, Essex, United Kingdom

    Background/Purpose: The SARS CoV-2 pandemic has inspired new interest in understanding the fundamental pathology of pneumonia and Acute Respiratory Distress Syndrome (ARDS). SARS CoV-2 in…
  • Abstract Number: 1052 • ACR Convergence 2020

    Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska

    Joanna Marco1 and Elizabeth Ferucci2, 1University of Washington, Seattle, WA, 2Alaska Native Tribal Health Consortium, Anchorage, AK

    Background/Purpose: Many connective tissue diseases are known to cause interstitial lung disease (ILD). American Indian/Alaska Native (AI/AN) populations have higher prevalence and severity of a…
  • Abstract Number: 0279 • ACR Convergence 2020

    Pulmonary Involvement in a Single Center Cohort of Patients with Systemic Lupus Erythematosus

    Naci Senkal1, Esen Kiyan2, Elif Kocasoy-Orhan3, Ali Demir4, Mehmet Aydogan5, Yasemin Yalcinkaya6, Ahmet Gul6, Murat Inanc7, Mahdume Lale Öcal6 and Bahar Artım-Esen6, 1Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, 2Department of Chest Disease, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, 3Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, 4Fulya Radiologic Imaging Center, İstanbul, Turkey, 5Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, 6Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, 7Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Background/Purpose: The prevalence of SLE pulmonary involvement varies depending on several factors, including diagnostic methods. In this study, we sought to determine the frequency of…
  • Abstract Number: 1200 • ACR Convergence 2020

    Serum Anti-PAD4 and Anti-PAD3/4XR Antibodies in Rheumatoid Arthritis Associated-Interstitial Lung Disease Are Associated with Better Lung Function

    Tim Wilson1, Joshua Solomon2, Jeffrey Swigris2, Erika Darrah3 and M Kristen Demoruelle1, 1University of Colorado, Denver, CO, 2National Jewish Health, Denver, CO, 3Division of Rheumatology, Johns Hopkins University, Baltimore, MD

    Background/Purpose: Rheumatoid arthritis (RA) associated-interstitial lung disease (ILD) affects approximately 10% of RA patients. It is a leading cause of morbidity and mortality, which is…
  • Abstract Number: 0383 • ACR Convergence 2020

    Sex Differences in Severity and Progression of Interstitial Lung Disease in Systemic Sclerosis: What We Have Learned from Clinical Trials

    Elizabeth Volkmann1, Ning Li2, Michael Roth2, Carol Feghali-Bostwick3, Richard Silver4, DeAnna Baker Frost5, Shervin Assassi6, Grace Kim2, Jonathan Goldin2 and Donald Tashkin2, 1University of California, Los Angeles, Los Angeles, CA, 2University of California, Los Angeles, Los Angeles, 3The Medical University of South Carolina, Charleston, SC, 4Medical University of South Carolina, Charleston, 5The Medical University of South Carolina, Charleston, 6University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX

    Background/Purpose: Although systemic sclerosis (SSc) disproportionately affects females compared with males [1], observational studies have demonstrated higher mortality rates in males with SSc [2]. This…
  • Abstract Number: 1244 • ACR Convergence 2020

    Clinical Characteristics and Outcomes in Patients with Primary Sjögren’s Syndrome-Associated Interstitial Lung Disease

    Joanna Marco1, Gregory Gardner1 and Nishant Gupta2, 1University of Washington, Seattle, WA, 2University of Cincinnati, Cincinnati

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune exocrinopathy that features interstitial lung disease (ILD) in up to 16% of patients. The clinical characteristics…
  • Abstract Number: 867 • 2019 ACR/ARP Annual Meeting

    Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial

    Mark Nicolls1, David Badesch 2, Lorinda Chung 3, Robyn Domsic 4, Thomas Medsger 5, Ashley Pinckney 6, Lynette Keyes-Elstein 6, Carla D'Aveta 6, Meagan Spychala 6, R James White 7, Paul Hassoun 8, Fernando Torres 9, Jerry Molitor 10, Dinesh Khanna 11, Holden Maeker 12, Beverly Welch 13, Ellen Goldmuntz 14, Roham Zamanian 1 and -- On Behalf of ASC01 Investigators 15, 1Stanford University, Stanford, 2University of Colorado, Denver, 3Stanford University, Palo Alto, CA, 4University of Pittsburgh, Pittsburgh, PA, 5University of Pittsburgh, Pittsburgh, 6Rho Federal Systems, Durham, 7University of Rochester, Rochester, NY, 8Johns Hopkins School of Medicine, Baltimore, 9UT Southwestern, Dallas, 10University of Minnesota, University of Minnesota, 11Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, 12Stanford, Stanford, 13National Institute of Allergy and Infectious Diseases, NIH, Bethesda, 14NIAID, Washingto, DC, 15---, USA

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc). Pre-clinical and clinical data have strongly implicated immune dysregulation and B cell…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology